Table 2.
Exposure to any TNFi by pediatric patients at CoA residing in Alabama
| Characteristic | Value |
|---|---|
| n | 1033 |
| Age at initial usage (median, IQR) | 13.0 (9.2–15.8) |
| Years of exposure (median, IQR) | 1.0 (0.17–2.4) |
| Female | 592 (57%) |
| Race | |
| Caucasian | 771 (75%) |
| African-American | 251 (24%) |
| Other / unknown | 11 (1.1%) |
| Number of TNF inhibitors used | |
| 1 | 768 (74%) |
| 2 | 227 (22%) |
| 3 | 37 (3.6%) |
| 4 | 1 (0.1%) |
| Diagnosis | |
| JIAa | 544 |
| IBDa | 265 |
| IBD with JIAa | 69 |
| Vasculitis | 33 |
| Uveitis | 31 |
| Psoriasis | 29 |
| Sarcoidosis | 17 |
| Mixed connective tissue disease / SLE | 13 |
| Sjogren Syndrome | 7 |
| Recurrent fever syndrome | 6 |
| Behcet Syndrome | 5 |
| Hidradenitis | 3 |
| Juvenile dermatomyositis | 3 |
| Non-infectious osteomyelitis | 3 |
| Sensorineural hearing loss | 2 |
| Otherb | 3 |
| Cases of Tuberculosis | 1 |
Abbreviations: IBD inflammatory bowel disease, JIA Juvenile idiopathic arthritis, SLE systemic lupus erythematosus
aIncludes subjects with uveitis, psoriasis, or both
bIncludes one each of chronic granuloma annulare, pityriasis rubra pilaris, and orbital pseudotumor